Anal Cancer Market Analysis & Forecast: 2026-2033

Anal Cancer Market Size and Share Analysis - Growth Trends and Forecast (2026 - 2033)

The global anal cancer market size is estimated to reach USD 1,099.9 Mn in 2026 and is projected to grow at a CAGR of 6.3% during the forecast period (2026-2033), surpassing USD 1,686.9 Mn by 2033. This is attributable to rising incidence of anal cancer, growing awareness of early cancer screening, increasing prevalence of human papillomavirus (HPV) infections, and expanding availability of targeted therapies and immunotherapies. For 2026 in the United States, the American Cancer Society estimates about 11,270 new anal cancer cases, around 3,570 in men and 7,700 in women, and roughly 1,700 deaths, including about 570 men and 1,130 women.

Key Takeaways from the Anal Cancer Market Report

• fluorouracil is projected to lead the market with a share of 39% in 2026 due to its widespread use as a standard component of concurrent chemoradiotherapy for anal cancer. For instance, recent
• Squamous cell carcinoma is set to account for the largest market share of 86% in 2026 because it accounts for the vast majority of anal cancer cases worldwide. For instance, nearly 9 out of 10 cases of anal cancers in the United States are squamous cell cancer, as per the
• Chemotherapy is slated to remain the most preferred treatment type with a market share of 44% in 2026 due to its widespread use as the standard treatment for anal cancer. For example, according to the 2025 SEOM-GEMCAD-TTD Clinical Guidelines, about 79% of anal cancer patients are diagnosed with localized (50%) or regional (29%) disease, for whom concurrent chemoradiotherapy remains the standard-of-care.
• North America is expected to dominate the global anal cancer industry with a share of 40% in 2026 due to its high healthcare spending, widespread access to advanced oncology therapies, and well-established reimbursement systems. For instance, cancer medicine spending reached USD 252 billion globally in 2024 and is projected to reach USD 441 billion by 2029, with the U.S. remaining the world's largest oncology market.
• Asia Pacific, registering a CAGR of 8.6%, is poised to emerge as the fastest-growing market for anal cancer treatments during the forecast period, thanks to expanding oncology infrastructure, increasing cancer awareness, improving access to advanced therapies, and a growing patient population.

Anal Cancer Market Overview

The global anal cancer market is expected to register steady growth during the forecast period. This is primarily due to increasing incidence of anal cancer, growing awareness regarding early diagnosis, advancements in cancer screening technologies, and availability of innovative treatment options.

Rising adoption of targeted therapies, immunotherapies, and minimally invasive treatment approaches is also supporting market expansion. In addition, favorable government initiatives, increased healthcare expenditure, and ongoing clinical research aimed at developing more effective therapies are contributing to market growth.

Anal cancer is an uncommon type of cancer that begins in or just inside the anal opening. Anal cancer can be classified into different types, including carcinoma in situ, squamous cell carcinoma, melanoma, adenocarcinoma, and basal cell carcinoma. Carcinoma in situ refers to stage 0 anal cancer, in which the cancerous cells remain only at the site of their origin and do not spread to other parts of the body. The anal canal is lined with flat squamous cells, and when these cells become cancerous, they give rise to squamous cell carcinoma, which is the most common type of anal cancer.

Melanoma begins in the cells responsible for producing melanin, the pigment that gives the skin and anal lining their color. Adenocarcinoma begins in the mucus-producing glands located beneath the anal lining. Basal cell carcinoma occurs in the perianal skin (the skin around the anus).

Some of the common symptoms of anal cancer include swelling around the anus, bleeding from the anus, anal discharge, irregular bowel movements, and others. Anal cancer can be treated using chemotherapy, surgery, immunotherapy, radiation therapy, or a combination of these treatments.

Rising global incidence of anal cancer is expected to boost growth of anal cancer treatment market during the forecast period. According to recent studies, the incidence of anal squamous cell carcinoma (SCC) has been increasing by about 1–3% per year in some developed countries. This trend, in turn, is creating a conducive environment for the expansion of anal cancer industry.

Increasing investment in oncology research and clinical trials is also supporting market expansion. Pharmaceutical companies, research institutions, and government organizations are increasing investments in developing novel therapies, biomarkers, and precision medicine approaches. This robust R&D pipeline is expected to drive future market expansion.

Segmental Insights 

To learn more about this report, Request Free Sample

Which Drug Type Dominates the Anal Cancer Market?

Fluorouracil to Lead with Nearly Two-Fifths of Market Share in 2026

According to Coherent Market Insights' latest anal cancer market analysis, fluorouracil is expected to account for 39% of the market revenue in 2026. This dominance is attributed to its established role as a key component of first-line concurrent chemoradiotherapy for anal squamous cell carcinoma, particularly in combination with mitomycin and radiation therapy. The treatment regime has been showing favorable results, such as better disease control and sphincter preservation, thus it is considered the most preferred approach to treatment.

The widespread adoption of fluorouracil-based chemoradiotherapy is supported by robust clinical evidence. In the long-term Phase III RTOG 98-11 (67.8% vs. 57.8%; P=0.006) and overall survival (78.3% vs. 70.7%; P=0.026) than the fluorouracil plus cisplatin regimen. These findings suppor fluorouracil-based chemoradiotherapy with mitomycin as the preferred first-line treatment for localized anal cancer.

Fluorouracil's widespread availability, cost-effectiveness, and inclusion in standard treatment guidelines continue to support its strong market position. In addition, improvements in chemotherapy delivery and expanding access to oncology care in emerging markets are expected to sustain demand during the forecast period.

Which Cancer Type Accounts for the Largest Anal Cancer Market Share?

Squamous Cell Carcinoma Set to Account for the Largest Market Share in 2026 

To learn more about this report, Request Free Sample

By cancer type, squamous cell carcinoma is projected to lead the market, accounting for a prominent share of 86% in 2026.  This is due to its high prevalence, as approximately 85% of anal cancer cases are diagnosed as squamous cell carcinoma. Similarly, increasing awareness, earlier diagnosis through screening programs in high-risk populations, and availability of well-established treatment protocols, including chemoradiation and immunotherapy for advanced disease, are boosting segment growth.

In addition, ongoing clinical research evaluating targeted therapies and immune checkpoint inhibitors for squamous cell carcinoma is expected to improve treatment outcomes. This, in turn, is likely to further drive demand for anal cancer drugs as well as strengthen the position of the target segment in the global anal cancer market during the projection period.

Anal Cancer Market Growth Drivers

Rising Incidence of HPV-Associated Anal Cancer

Increasing cases of HPV-associated anal cancer are fueling growth of anal cancer market. Multiple studies indicate that about 80% to 97% of people diagnosed with anal cancer are also infected with HPV. Persistent infection with high-risk human papillomavirus (HPV), particularly HPV-16, is the leading cause of anal cancer and is detected in most cases. According to IARC-based global estimates, around 35,000 new anal cancer cases annually are attributable to HPV infection. Rising HPV-driven disease burden, especially among high-risk groups such as immunocompromised individuals, is increasing demand for anal cancer diagnostics and treatment.

Anal Cancer Market Opportunities

Increasing Adoption of Early Screening and Advanced Diagnostics

Rising awareness of anal cancer risk factors is driving wider adoption of screening methods such as anal cytology, HPV testing, and high-resolution anoscopy (HRA). Earlier diagnosis improves treatment outcomes and increases the number of patients eligible for therapy. This is expected to create lucrative growth opportunities for the anal cancer market during the forecast period.

Anal Cancer Market Trends

Shift Towards Immunotherapy-based Treatments

Increasing use of immune checkpoint inhibitors for advanced, recurrent, and metastatic anal cancer is emerging as a key growth-shaping trend in the anal cancer treatment market. The treatment landscape is gradually evolving with the introduction of immunotherapy options such as PD-1 inhibitors, along with investigational targeted therapies. Ongoing clinical trials and regulatory developments are expanding treatment options beyond conventional chemoradiotherapy, particularly for patients with relapsed or advanced disease. These advancements are expected to support market growth over the forecast period.

Current Events and Their Impact on the Anal Cancer Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Regional Insights 

To learn more about this report, Request Free Sample

Rising Anal Cancer Burden Driving Market Growth in North America

North America is expected to account for around 40% share of the global anal cancer market in 2026. This dominance is attributable to high awareness of HPV-related cancers, increasing prevalence of anal cancer, and rising adoption of advanced treatment options such as chemoradiotherapy and immunotherapy.

According to the American Cancer Society, the estimated number of new anal cancer cases in the United States for 2026 is about 11,270, including 3,570 in men and 7,700 in women. Similarly, the estimated number of deaths is about 1,700. These statistics indicate that the North America anal cancer market outlook will remain positive during the forecast period.

Asia Pacific Anal Cancer Market Trends

Asia Pacific is anticipated to emerge as a highly lucrative market for manufacturers of anal cancer drugs during the forecast period, recording a CAGR of 8.6%. This is mostly due to increasing patient pool, improving healthcare infrastructure, rising awareness of HPV-related diseases, and expanding access to cancer screening and vaccination programs. Similarly, continued preference for chemotherapy and supportive government policies are boosting growth of Asia pacific anal cancer market.

Anal Cancer Market Outlook – Country-wise

U.S. Anal Cancer Market Forecast

The United States is expected to remain a leading market for anal cancer treatments during the forecast period. This can be attributed to strong screening systems, high HPV vaccination awareness, and rapid access to advanced treatments such as chemoradiotherapy and immunotherapy. The country also benefits from active clinical research and early adoption of novel oncology therapies, which improves diagnosis and patient outcomes.

China Anal Cancer Market Trends

China is projected to witness steady growth in the anal cancer market due to improving cancer diagnostic infrastructure, rising awareness of HPV-related diseases, and expanding access to oncology care across urban and semi-urban regions. Increasing availability of HPV screening and gradual adoption of modern treatment approaches are improving detection rates, though late diagnosis remains common.

Who are the Major Companies in the Anal Cancer Market?

Some of the major players in anal cancer market are Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited.

Key Strategies Adopted by Industry Players

Top manufacturers of anal cancer drugs are adopting various organic and inorganic strategies to boost their sales as well as gain a competitive edge over the industry. These include new product launches and approvals, investments in R&D, clinical trials, mergers, acquisitions, distribution agreements, partnerships, collaborations, and joint ventures.

• In March 2026, the European Commission approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for first-line treatment of adults with advanced squamous cell carcinoma of the anal canal (SCAC). This approval provides a new treatment option from Incyte for patients with advanced or inoperable SCAC in Europe.
• In May 2025, the U.S. FDA approved Incyte’s retifanlimab-dlwr with carboplatin and paclitaxel for first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). This approval provided a new treatment option for patients with advanced SCAC in the United States.

Market Report Scope 

Analyst Opinion (Expert Opinion)

• Anal cancer treatment demand is largely driven by HPV-related disease burden. Around 90% of anal cancers are linked to human papillomavirus (HPV), making HPV prevention, screening, and treatment strategies key factors influencing the market.
• Most anal cancer cases are diagnosed as squamous cell carcinoma. Nearly 9 out of 10 anal cancers are squamous cell carcinoma, creating consistent demand for therapies specifically designed for this subtype. It also encourages continued investment in chemoradiotherapy, immunotherapy, and clinical research focused on squamous cell carcinoma.
• The increasing use of immunotherapy is improving treatment options. Checkpoint inhibitors are expanding treatment choices for patients with advanced or recurrent anal cancer who have limited alternatives. This supports innovation and increases adoption of novel oncology therapies.
• Greater awareness among high-risk populations is supporting earlier diagnosis. Increased screening efforts for people with persistent HPV infection, HIV, and other high-risk conditions are helping detect disease at earlier stages. This, in turn, is expected to boost demand for diagnostic tests, screening services, and timely treatment interventions during the forecast period.

Market Segmentation

• By Drug Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Fluorouracil
  • Cisplatin
  • Carboplatin
  • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
• By Cancer Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Carcinoma In-situ
  • Squamous Cell Carcinoma
  • Melanoma
  • Adenocarcinoma
  • Basal Cell Carcinoma
• By Treatment Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Immunotherapy
• By Distribution Channel Insights ( Revenue, USD Mn, 2021 - 2033)
  • Hospitals & Clinics
  • Research & Academic Institutes
  • Long-term Care Centers
  • Pharmacies
• By Region Insights ( Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  •  Africa
    • North Africa
    • Central Africa
    • South Africa

Sources

Primary Research Interviews

• Oncologists
• Colorectal Surgeons
• Radiation Oncologists
• Medical Oncologists
• Hospital Procurement Managers
• Cancer Research Scientists
• Pharmaceutical & Biotechnology Executives
• Diagnostic Laboratory Specialists
• Key Opinion Leaders (KOLs)

Databases

• PubMed
• MEDLINE
• Embase
• ClinicalTrials.gov
• SEER (Surveillance, Epidemiology, and End Results Program)
• GLOBOCAN
• WHO Global Health Observatory (GHO)
• National Cancer Database (NCDB)

Magazines

• Cancer Today
• Oncology Times
• The ASCO Post
• Cancer World
• Oncology Nursing News

Journals

• The Lancet Oncology
• Journal of Clinical Oncology
• JAMA Oncology
• Annals of Oncology
• Cancer
• International Journal of Radiation Oncology, Biology, Physics
• Clinical Cancer Research
• BMC Cancer

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• USA Today
• The Guardian

Associations

• American Society of Clinical Oncology (ASCO)
• American Cancer Society (ACS)
• European Society for Medical Oncology (ESMO)
• National Comprehensive Cancer Network (NCCN)
• American Association for Cancer Research (AACR)
• Union for International Cancer Control (UICC)
• European Society of Surgical Oncology (ESSO)

Public Domain Sources

• World Health Organization (WHO)
• National Cancer Institute (NCI)
• Centers for Disease Control and Prevention (CDC)
• International Agency for Research on Cancer (IARC)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)
• UK National Health Service (NHS)
• Cancer Research UK

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years